跳至主要内容
临床试验/NCT04212715
NCT04212715招募中2 期

Prostate SABR With Intra-Prostatic SABR Boost: A Phase II Study

King Saud University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年12月26日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
30
试验地点
1
主要终点
Acute Toxicity

研究概览

简要总结

Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Histologically confirmed prostate adenocarcinoma
  • High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA > 20 ng/mL
  • Willing to give informed consent to participate in this clinical trial

排除标准

  • Prior pelvic radiotherapy
  • Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
  • Contraindication to prostate MRI
  • No evidence of castrate resistance (defined as PSA < 3 ng/ml while testosterone is < 0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.
  • Definitive extrapelvic nodal or distant metastatic disease on staging investigations.

结局指标

主要结局

Acute Toxicity

时间窗: 3 month after accrual is completed

To document the rate of acute urinary and bowel toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) criteria

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Yasir Alayed

Consultant and Assistant Professor

King Saud University

研究点 (1)

Loading locations...

相似试验